EU's von der Leyen survives parliament confidence vote brought by far-right
As expected, the motion failed to get the two-thirds majority it needed to pass. Only 175 members of parliament backed the motion, while 360 voted against and 18 abstained.
Romanian nationalist Gheorghe Piperea, the lead sponsor of the motion, had criticized among other things the Commission's refusal to disclose text messages between von der Leyen and the chief executive of vaccine maker Pfizer during the COVID-19 pandemic.
'The decision-making has become opaque and discretionary, and raises fears of abuse and corruption. The cost of obsessive bureaucracy of the European Union such as (tackling) climate change has been a huge one,' Piperea told the parliament on Monday.
During the debate on her leadership, von der Leyen defended her record in parliament, rejecting criticism of her management of the pandemic and asserting that her approach ensured equal vaccine access across the EU.
Although the censure motion had little chance of success, it was a political headache for von der Leyen as her Commission negotiates with US President Donald Trump's administration to try to prevent steep US tariffs on EU goods.
It was the first time since 2014 that a Commission president has faced such a motion. Then President Jean-Claude Juncker also survived the vote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...
Net Sales: SEK178 million in Q2, with an organic growth of -11%. Gross Margin: Stable at 74% for both Q2 and year-to-date. Adjusted EBITDA: 13% for the quarter. Thoracic Sales: SEK105 million in Q2, with an organic growth of -19%. Lung Sales: Negative growth of -10% in local currencies; however, outside the largest US customer, lung sales grew by 26%. Heart Sales: SEK3 million in Q2, compared to SEK19 million last year. Abdominal Sales: SEK52 million, with an organic growth of 19%. Liver Sales Growth: 28% in local currencies, with 32% growth in main European markets. Kidney Sales: Declined by 2%, but US Kidney Assist Transport disposables grew by 47%. Services Sales: SEK21 million, with organ recovery part decreasing by 19%. Operating Cash Flow: Positive SEK9 million in Q2. Investments: SEK72 million, primarily for US clinical trials and perfusion devices. Release Date: July 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Xvivo Perfusion AB (XVIPF) reported strong growth in specific segments, with US lung sales to clinics and OPOs growing by 26%, liver sales in Europe increasing by 32%, and kidney sales in the US rising by 47% during the second quarter. The company achieved significant milestones for future growth, including a 76% risk reduction in severe PGD from the European Heart Study, which led to improved patient survival. There is a high interest in starting EVLP programs, with four new XPS customers in the US in the first six months of 2025, indicating potential for future growth. Xvivo Perfusion AB (XVIPF) maintained a stable gross margin of 74% despite currency headwinds, demonstrating resilience in its business model. The company is preparing for the launch of heart products in Europe and has seen high interest from clinics, indicating potential for future revenue growth in this segment. Xvivo Perfusion AB (XVIPF) reported negative top-line growth in Q2 2025 compared to the same quarter last year, primarily due to a slower-than-expected lung market, lack of heart sales, and a weaker US dollar. The company's EBITDA as a percentage of sales decreased this quarter, reflecting challenges in maintaining profitability amidst sales declines. There was a significant destocking issue with the largest US lung customer, impacting sales negatively by approximately USD 1.5 million. Heart sales were significantly lower in Q2 2025 compared to last year, with only SEK3 million in sales versus SEK19 million last year, due to the absence of trial revenue. The US service business progress was unsatisfactory, with a strategic review indicating a need for improvement in this area. Q: Can you provide more details on the destocking issue with your largest lung customer and when it might end? A: The destocking was unexpected due to slower growth in the EVLP market. It will likely stop when the market returns to normal growth levels. If the market stabilizes, we don't expect further inventory reductions. The impact in Q2 was approximately USD 1.5 million. Christoffer Rosenblad, CEO Q: With new EVLP centers ramping up in the US, do you expect growth from direct US lung customers to accelerate? A: We aim to accelerate growth by investing in customer-facing personnel to ramp up new accounts. We are planning for a better second half compared to the first half. Christoffer Rosenblad, CEO Q: What is the expected sales contribution from heart products in Europe if approval is received in Q3? A: Sales will ramp up gradually as we list the product country by country and activate clinics. We expect increasing sales quarter-on-quarter rather than a high initial launch volume. Christoffer Rosenblad, CEO Q: What is the status of the liver trial and the continuous access protocol for heart in the US? A: The first patient for the heart protocol could be any day, depending on waitlist matching. For the liver trial, we aim to include the first patient by the end of Q3. Christoffer Rosenblad, CEO Q: How is the interest from OPOs affecting your strategy, and what is the timeline for supporting them? A: We see OPOs as a crucial customer group due to the NRP trend. We have some homework to do to best cooperate with them, but we expect to be ready to support them in less than 12 months. Christoffer Rosenblad, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Even A.I. Might Not Be Able To Save These New Style
North American and European brands have been successfully selling made-in-China goods for decades. It was probably inevitable that many of its small factories would become direct online sellers, perhaps in competition with their former customers. But the trademarks that many of them have been using may not be helping them crack the market. American companies – and startups are certainly no different – give a lot of thought to the best mark, which will personify their product, using a name which helps it to sell, yet also distinguishes it from its competition. All companies should also search their marks to be sure they do not come too close to a potential competitor which may demand a name change, or worse, threaten to sue. Many Chinese startups have taken a different path. They are adopting made-up names which bear little resemblance to the traditional English or Romance language sounding words we usually see. Consider this random assortment I came up with: 'Lvrigfpro' for pharmaceuticals 'Matdg' for jewelry 'Mahcscha' for beach towels 'Bfxlmki' for paintings and paper 'Haisiwlkj' for furniture covers 'RabvPerce' for toys A number of these brands are setting new paradigms by using a combination of consonants and vowels which don't follow familiar patterns, making them arguably a little difficult to recognize and to pronounce. These contrast sharply with now-household names of many Chinese brands with a gigantic U.S. presence – brands such as: 'Tik Tok' 'Alibaba' 'Huawei' 'Shein' 'Haier' Pronunciation can always be a challenge for brands coming into the U.S. from overseas. All of the well-known brands listed above are capable of a pronunciation in English, largely because they still follow certain rules which combine consonants and vowels in a way that makes them understandable, even if initially pronunciation is unclear. Words have a certain flow, creating a kind of familiarity so that made-up words can sound like and be pronounced like a word in the English language. These marks follow the rules in a way that the other marks above which I randomly selected do not. Words are formed of syllables, and syllables are composed of a combination of consonants. The reader needs to build up a 'beat,' and words which are readily recognized will march to that beat. Interestingly, companies could save time and money in the trademark creation process by coming up with something that feels unfamiliar, like 'Haisiwlkj.' One interesting aspect of these marks is that while I always counsel startup companies to adopt a mark that they will be able to protect and to register in the U.S. Patent and Trademark Office, it is also desirable that the words look, appear and sound different from anything already in use in traditional terms; this equates to a stronger, more distinctive trademark. The chances of running into another mark already used with a similar appearance, sound and meaning seem small. So, two of the three goals of brand name creation are fulfilled: (1) first, do no harm (avoid conflicting with others); (2) get something you can protect (make it distinctive as possible); (3) as for the third, which is 'pick a name that will sell the product' – maybe not so much. (Marketers accuse lawyers of preferring 1 and 2 over 3, and in many cases, they're not wrong. What's the use of having a mark if it doesn't help actually sell the product?) The great inherent value to using the right word for a brand is the benefit of projecting the right image, taking into account an enormous range of cultural preferences which range from the literal messages words or portions of words suggest, to a sound of familiarity which elicits good or positive feelings, or reflects certain values. All of that is lost in brand names which are not only fanciful creations, but which fail to send a message to a consumer who is busy trying to figure out exactly what the word is and how you would pronounce it. Given the roles trademarks play in conveying meaning or evoking emotion, these new marks may be losing out on the main branding opportunity. The U.S. market has since the very beginning featured 'foreign' products, and often many of those products have had the greatest of prestige. Not all of them have been inherently easy for American consumers to pronounce, whether from Europe, Asia, or elsewhere. But they have had a certain common element to them much more familiar to the American and English language speaker's ear than this newest generation of trademarks. Over time, people become accustomed to and comfortable with new things. Will these neologisms start to sound familiar once there are enough of them in everyday use, or will they fade in favor of more traditional sounding words? There's always a back story. The explosion in trademark applications from China in recent years has actually been well documented. Lawyers who practice regularly in front of the U.S. Patent and Trademark Office also recognize certain patterns among some segment of these applications. A word is created, and a web page is thrown together to show the product being offered for sale. Many of these applications are accused of being filed simply to try to reserve rights, and names are even more blatantly just to get applications on file in the Trademark Office for the benefit of certain subsidies that were being offered by the Chinese government to obtain U.S. trademark registration protection. The flood of these offbeat names in the Trademark Office has its own story. Official investigations by the United States Patent and Trademark Office have indicated the Chinese government, at every level from national to local, has incentivized companies to seek to develop and protect their brands abroad, including in the U.S.A. In many cases some government agency paid the bill not only for the cost of applications in the Trademark Office, but even allowed the trademark owner to end up with a surplus for each trademark application they file in the United States. Over the past few years, the Trademark Office has even taken some enforcement actions where it has found that some of these practices violate the good faith rule that any application exhibits a 'bona fide intent' to use the mark in the United States. Will American consumers accept and become familiar with these names and come to appreciate them as trusted brands? Or is this only a phase during which time these non-U.S. marketers and non-English language natives are making an all-out assault to project and protect brand names into the United States for their own purposes? Putting aside the tariffs in the room, it would otherwise seem that direct-to-consumer marketing from these small China-based enterprises which formerly relied on U.S. entities to sell their wares is not likely to die down. They presumably will change their branding habits – through time, experience, and maybe even the assistance of A.I. – to develop words and names that look more like the types of familiar terms that will motivate American shoppers to trust those brands and remember the names. You might say that this process will be more consonant with consumer expectations.
Yahoo
an hour ago
- Yahoo
Has the Barclays share price hit a peak?
The Barclays (LSE:BARC) share price has delivered a 191% gain over the past five years. Yes, that was from a low base, but investors could still have picked up shares in the bank for 130p in late 2023. Today, the banking stock trades for 343p a share. What's more, if an investor bought stock around 130p, they'd also have locked in a very sizeable dividend yield. If I'm not mistaken, the yield was around 5.5% when I built most of my position in 2023. This performance has been underpinned by the bank's ongoing strategic transformation, strong financial results, a renewed focus on efficiency and diversification, and a vast improvement in investor sentiment. These factors were most apparent in the first quarter earnings. The group reported an 11% year-on-year increase in total income to £7.7bn, with profit before tax rising 19% to £2.7bn. The investment banking division stood out, posting a 16% revenue increase and capitalising on heightened market volatility. The bank's return on tangible equity (RoTE) — a key metric for measuring profitability in finance — reached 14% for the quarter. That's well above the group's unchanged full-year target of around 11%. Management also upgraded net interest income guidance for 2025. This is further evidence that the strategic transformation's already delivering tangible results. Recent acquisitions including Tesco Bank, and expansion into private credit have diversified revenue streams and reduced reliance on more cyclical segments. However, the question remains whether Barclays' share price has peaked. The current valuation, with a price-to-earnings (P/E) ratio of around 8.4, remains discounted compared to many global bank peers. This suggests there could still be room for further appreciation if the bank continues to deliver on its strategic objectives and market conditions remain supportive. This P/E figure falls to six times by 2027, while the dividend yield grows from 2.6% to 3.4%. However, risks to the outlook are significant. Macroeconomic uncertainty persists, with concerns about global growth and rising US debt. Moreover, UK house price declines potentially impact credit quality and consumer demand. Barclays' US Consumer Bank division continues to struggle, and any deterioration in the US economy could weigh on group results Personally, I'm not adding to my position in Barclays. But the reason is concentration risk. A lot of my invested capital is in Barclays and Lloyds. Adding more probably wouldn't be wise. However, that doesn't mean I'm not bullish over the long run. Avoiding any economic disaster I'd expect the stock to make steady gains. And one reason for that is the interest rate environment. If central bank rates sit between 2% and 3.5% in the long run, and the economy chugs along, it's likely to be a profitable environment for lenders. This is crucial for banks. And that's why I believe Barclays is certainly worth considering. The post Has the Barclays share price hit a peak? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has positions in Barclays Plc and Lloyds Banking Group Plc. The Motley Fool UK has recommended Barclays Plc and Lloyds Banking Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
